• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.

    5/12/25 10:43:30 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TMDX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    TRANSMEDICS GROUP INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    89377M109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    89377M109


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,057,076.96
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,058,396.34
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,058,396.34
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    89377M109


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,058,396.34
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,058,396.34
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TRANSMEDICS GROUP INC
    (b)Address of issuer's principal executive offices:

    200 Minuteman Road,Andover,MA,US,01810
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    89377M109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5058396.34
    (b)Percent of class:

    15.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    5058396.34

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TRANSMEDICS GROUP INC. No one other person's interest in the COMMON STOCK of TRANSMEDICS GROUP INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:05/09/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:05/09/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $TMDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMDX

    DatePrice TargetRatingAnalyst
    12/17/2024$116.00 → $75.00Overweight → Neutral
    Analyst
    11/22/2024Buy → Hold
    Needham
    10/29/2024$200.00 → $125.00Outperform
    Oppenheimer
    10/29/2024$208.00 → $109.00Buy
    Needham
    9/24/2024$200.00Outperform
    Robert W. Baird
    8/21/2024$208.00Buy
    Needham
    6/6/2024$161.00Overweight
    Cantor Fitzgerald
    6/4/2024$151.00Overweight
    Stephens
    More analyst ratings

    $TMDX
    Financials

    Live finance-specific insights

    See more
    • TransMedics Reports First Quarter 2025 Financial Results

      ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

      5/8/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025

      ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domesti

      4/24/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results

      ANDOVER, Mass., Feb. 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024. Recent Highlights  Total revenue of $121.6 million in the fourth quarter of 2024, a 50% increase compared to the fourth quarter of 2023Total revenue of $441.5 million in the full year of 2024, an 83% increase compared to the full year 2023Generated net income of $

      2/27/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Leadership Updates

    Live Leadership Updates

    See more
    • TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

      ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem

      12/2/24 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

      9/26/24 6:04:00 PM ET
      $CCRN
      $CHK
      $ENSG
      $SITC
      Professional Services
      Consumer Discretionary
      Oil & Gas Production
      Energy
    • TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary

      ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be

      7/26/23 5:09:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      10/7/24 11:37:08 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      10/4/24 4:23:23 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by TransMedics Group Inc. (Amendment)

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      2/14/24 6:28:57 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TransMedics Group downgraded by Analyst with a new price target

      Analyst downgraded TransMedics Group from Overweight to Neutral and set a new price target of $75.00 from $116.00 previously

      12/17/24 8:22:54 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Group downgraded by Needham

      Needham downgraded TransMedics Group from Buy to Hold

      11/22/24 8:05:47 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Oppenheimer reiterated coverage on TransMedics Group with a new price target

      Oppenheimer reiterated coverage of TransMedics Group with a rating of Outperform and set a new price target of $125.00 from $200.00 previously

      10/29/24 7:47:16 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TransMedics Reports First Quarter 2025 Financial Results

      ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

      5/8/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025

      ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domesti

      4/24/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      ANDOVER, Mass., April 2, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on March 28, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 1,570 shares of its common stock and an aggregate of 1,043 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4)

      4/2/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.

      SCHEDULE 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      5/12/25 10:43:30 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by TransMedics Group Inc.

      144 - TransMedics Group, Inc. (0001756262) (Subject)

      5/9/25 4:02:59 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by TransMedics Group Inc.

      10-Q - TransMedics Group, Inc. (0001756262) (Filer)

      5/8/25 4:15:56 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Basile Edward M exercised 6,000 shares at a strike of $0.70 and sold $693,780 worth of shares (6,000 units at $115.63) (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      5/13/25 5:43:42 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Commercial Officer Khayal Tamer I sold $183,967 worth of shares (2,407 units at $76.43), decreasing direct ownership by 6% to 36,042 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      3/5/25 4:30:17 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President & CEO Hassanein Waleed H was granted 59,781 shares, increasing direct ownership by 97% to 121,424 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      2/26/25 6:16:52 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care